← All trials
NCT06410352
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Mar 1, 2023
- Primary completion
- Apr 30, 2024
- Completion date
- Dec 31, 2026
- First posted
- May 13, 2024
- Last posted
- Oct 26, 2024
- Enrollment
- 220
- Arms / groups
- 4 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University Medical Center, KazakhstanLead sponsor
- Nazarbayev University Medical CenterCollaborator
- University Medical Center, KazakhstanSponsor investigator
- University Medical Center, KazakhstanOfficial
- Astana Medical UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.